Skip to main content
Tibet Duo Rui Pharmaceutical Co., Ltd. logo

Tibet Duo Rui Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301075 ISIN · CNE100004RW5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 874 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301075

About Tibet Duo Rui Pharmaceutical Co., Ltd.

https://www.duoruiyy.com

Tibet Duo Rui Pharmaceutical Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and distribution of chemical drug preparations. The company specializes in high-barrier generic drugs and therapeutic areas including plasma volume expansion, anti-infection, and cardiovascular health. Its flagship product line includes Hydroxyethyl Starch 130/0.4 Electrolyte Injections, which are utilized in clinical settings for the prevention and treatment of hypovolemia and shock. Duo Rui Pharmaceutical integrates a comprehensive supply chain encompassing raw material procurement, advanced manufacturing processes, and a nationwide marketing network. The company emphasizes technological innovation and quality control to provide clinical solutions for critical care and specialized medical needs.

Recent filings

Filing Released Lang Actions
北京大成律师事务所关于西藏多瑞医药股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter (“法律意见书”) issued by Beijing Dacheng Dentons Law Firm regarding the legality of the 2025 Annual Shareholders’ Meeting of Tibet Dorui Pharmaceutical Co., Ltd. It does not itself present financial results or proxy materials, nor is it announcing or publishing a report; rather, it is a compliance/attestation letter by external counsel. Under the classification rules, such officer certifications or legal opinion letters are treated as general regulatory filings (RNS) rather than AGM slides, proxy statements, or formal AGM materials.
2026-05-21 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the 2025 annual shareholders’ meeting resolutions for a listed company, detailing the meeting attendance and the voting results on various proposals. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-21 Chinese
关于变更股东会召开地点的公告
Proxy Solicitation & Information Statement Classification · 90% confidence The document is an announcement by 西藏多瑞医药股份有限公司 regarding a change of venue for its 2025 Annual General Meeting. It includes the notice of meeting, agenda items for shareholder voting, proxy authorization forms, registration procedures, and voting instructions – all indicative of proxy solicitation materials sent to shareholders to inform and request their votes. Therefore, it best fits the “Proxy Solicitation & Information Statement” category (PSI).
2026-05-15 Chinese
国金证券股份有限公司关于王庆太、曹晓兵要约收购西藏多瑞医药股份有限公司之2026年度第一季度持续督导意见
M&A Activity Classification · 85% confidence The document is a continuous supervision opinion (“持续督导意见”) prepared by the financial advisor for a tender offer acquisition of Tibet Duorui Pharmaceutical by Wang Qingtai and Cao Xiaobing. It covers detailed updates on the share transfer, fulfilment of commitments, board changes, and compliance with regulatory requirements during the first quarter of 2026. This is clearly part of the M&A regulatory process for a takeover bid, not an earnings release, annual report, or management discussion. Therefore, it falls under the M&A Activity category.
2026-05-12 Chinese
关于公司证券事务代表辞职的公告
Regulatory Filings
2026-04-28 Chinese
募集资金年度存放、管理与使用情况鉴证报告
Regulatory Filings
2026-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.